We have examined whether oral immunization of adult Swedish volunteers with a prototype enterotoxigenic Escherichia coli vaccine would induce antigen-specific T-cell responses in blood. Volunteers were given one to three doses of the whole-cell component of the vaccine, which consisted of formalin-inactivated bacteria expressing the fimbrial colonization factor antigens I and II. Following immunization, in vitro stimulation of blood mononuclear cells with the colonization factor antigens resulted in modest proliferative responses which were accounted for mainly by CD4+ T cells and, to a lesser extent, by CD8+ T cells. A main finding of this study was that a majority of the orally immunized volunteers had circulating T cells capable of producing large quantities of gamma interferon following in vitro exposure to either of the colonization factor antigens. No interleukin 2 production could be detected in the cell cultures. These results suggest that oral immunization of humans induces the migration of specific mucosal T immunocytes from the intestine into peripheral blood.
We have examined whether oral immunization of adult Swedish volunteers with a prototype enterotoxigenic Escherichia coli vaccine would induce antigen-specific T-cell responses in blood. Volunteers were given one to three doses of the whole-cell component of the vaccine, which consisted of formalin-inactivated bacteria expressing the fimbrial colonization factor antigens I and II. Following immunization, in vitro stimulation of blood mononuclear cells with the colonization factor antigens resulted in modest proliferative responses which were accounted for mainly by CD4+ T cells and, to a lesser extent, by CD8+ T cells. A main finding of this study was that a majority of the orally immunized volunteers had circulating T cells capable of producing large quantities of gamma interferon following in vitro exposure to either of the colonization factor antigens. No interleukin 2 production could be detected in the cell cultures. These results suggest that oral immunization of humans induces the migration of specific mucosal T immunocytes from the intestine into peripheral blood.
It is generally held that antigen administered in the gastrointestinal tract can induce activation of intestinal lymphocytes, a fraction of which may migrate via the mesenteric lymph nodes and the thoracic duct to the circulation before returning to the site of antigen encounter and to other mucosal tissues such as salivary and mammary glands. This migratory behavior has been extensively documented for mucosal B cells in both animal and human systems (7, 14, 21, 33) . In regard to the migration of T cells, it has been shown in adoptive cell transfer experiments that T blasts from mesenteric lymph nodes under certain conditions preferentially repopulate the gut upon transfer to syngeneic recipients (11, 22) . Furthermore, it has been demonstrated that antigen-specific T-helper cells arising in the Peyer's patches after intra-Peyer's patch immunization subsequently appeared in the thoracic duct, the intestinal epithelium, and the lamina propria of the gut (8) . The aim of the present study was to investigate whether intestinal T cells, which play an essential role in controlling B-cell proliferation and differentiation, would display similar migratory properties in humans.
We have recently developed a prototype vaccine against enterotoxigenic Escherichia coli (ETEC) (29, 30) , which is the most common enteropathogen in humans (4) . ETEC colonizes the small intestine by means of fimbrial colonization factor antigens (CFAs) and gives rise to diarrhea by the secretion of one or two enterotoxins. In previous studies, we have shown that oral immunization of human volunteers with this prototype ETEC vaccine evoked a specific mucosal immunoglobulin A (IgA) response in intestinal lavage fluid (1) and the transient appearance of CFA-specific IgA-and IgM-secreting cells in the circulation (34) . On the basis of these results, we examined whether oral immunization with the ETEC vaccine would give rise to vaccine-specific T cells in human peripheral blood.
(These results were presented in part at the 7th Interna- 14 were given two doses, and three were given three doses of the whole-cell component of a prototype ETEC vaccine that was produced by the Swedish National Bacteriological Laboratory. Each dose of vaccine, which consisted of 10" formalin-killed ETEC bacteria expressing CFA/I and CFA/II (comprising the coli surface components CS1, CS2, and CS3), was mixed with 150 ml of a sodium-bicarbonate-citric acid buffer (ACO Pharmachemicals, Stockholm, Sweden) and was given as a drink with 2-week intervals between immunizations (with the exception of four volunteers who were immunized with a 23-day interval). Volunteers fasted for 2 h before and 1 h after immunization. Ten to 50 ml of heparinized blood was collected from all volunteers before and at weekly intervals following each immunization.
Purified antigens. Purified CFA/I was prepared from a flagellum-deficient mutant strain of H10407 (078:K80:H11, heat-stable toxin/heat-labile toxin) by homogenization with a Waring blender followed by ammonium sulfate fractionation and negative DEAE Sephadex column chromatography (9) .
Purified CFA/II (CSl plus CS3) was prepared from strain E1392-75 (06:K15:H16, heat-stable toxin/heat-labile toxin) by homogenization followed either by salt precipitation and column chromatography (18) or by cesium chloride gradient ultracentrifugation (19) . The IL-2 assay. The IL-2 contents of cell microcultures were determined by the CTLL-2 bioassay of Gillis et al (10) . PBMC were cultured for 24 h with CFA/I, CFA/II, phytohemagglutinin, or medium alone, and thereafter supernatants were collected, frozen at -18°C, and assayed for IL-2 activity within 4 weeks. (Under these storage conditions, IL-2 activity in supernatants from phytohemagglutinin-stimulated PBMC remained stable for at least 4 months.) IL-2 activity in supernatants was determined by extrapolation from a standard curve generated by adding known amounts of purified recombinant human IL-2 (Genzyme Corporation, Cambridge, Mass.) to CTLL-2 cells and measuring cell proliferation by the incorporation of [6-3H]thymidine, as described above.
IFN--y assays. Numbers of IFN--y-secreting cells and amounts of cell-free IFN--y generated in cultures of PBMC exposed for 48 h to either of the two CFAs were determined by a sandwich enzyme-linked immunosorbent assay (ELISA) (2) and a reverse ELISPOT assay (6) , respectively. At the completion of the culture period, cells and supernatants were separated by centrifugation at 400 x g for 10 min. Supernatants from duplicate cultures were harvested and kept frozen at -20°C until being assayed by ELISA (see below). The cell pellets were resuspended with sterile PBS, washed twice, resuspended in complete culture medium, and assayed for numbers of IFN--y-secreting cells by ELISPOT (see below). The IFN--y-specific monoclonal antibodies used in both the ELISA and ELISPOT assay were purified by protein A affinity chromatography and were kindly provided by Gudrun Andersson (Research and Development Immunobiology, Kabi Biopharma, Stockholm, Sweden) (2).
( (6) . Statistics. The paired two-tailed Student's t test was used to assess the significance of differences between pre-and postimmunization values for each volunteer. The data were log transformed prior to statistical analysis ( Fig. 1 and Fig. 2 ). The Wilcoxon rank sum test was employed to assess differences between groups of nonimmunized and immunized individuals (Fig. 3) .
RESULTS
CFAII-and CFA/II-induced proliferative responses. Purified CFA/I and CFA/II were both capable of inducing in vitro proliferation of PBMC collected from volunteers orally immunized with the ETEC vaccine. Thus, cells from 10 of 13 vaccinees had a twofold or higher SI to CFA/I, and cells from 6 of 13 volunteers had a corresponding response to CFA/II (Fig. 1) . The arithmetic mean preimmune SI were 1.4 for CFAII and 1.7 for CFA/II. After immunization, SI increased on the average 2.8-fold after stimulation with CFA/I and 1.9-fold after stimulation with CFA/II; both these increases were statistically significant (Fig. 1) . Radioactive thymidine incorporation ranged from 1,000 to 5,000 cpm in cultures containing PBMC exposed to medium alone (negative control) and from 1,000 to 20,000 cpm (SI = 0 to 16) in cultures of CFA-stimulated PBMC from vaccinees. Incorporation of radioactive thymidine in cultures of PBMC exposed to phytohemagglutinin ranged from 50,000 to 150,000 cpm (SI = 30 to 150). Overall, CFA-induced proliferative responses were rather moderate and varied considerably between individuals.
We could also document that the proliferative responses to CFA/I and CFA/II were accounted for mainly by CD4+ T cells and, to a lesser extent, by CD8+ T cells (Fig. 2) . After immunization, a twofold or higher proliferative response to CFA/I and CFA/II was observed for the CD4+ T-cell fractions isolated from four of eight and three of eight volunteers, respectively. Corresponding results for the CD8+ T-cell fraction were two of eight and three of eight for CFA/I and CFA/II, respectively. A comparison between preimmune and postimmune SI revealed statistically significant differences for the CD4 fraction stimulated by either of the CFAs and for the CD8 fraction stimulated by CFAII (Fig. 2) IFN--y responses. We also determined the ability of PBMC isolated from oral vaccinees to produce IFN-y in response to in vitro-added CFAs. Only low levels of IFN-y were detected in the supernatants of PBMC isolated from eight nonimmunized individuals (arithmetic means, 54 and 24 mU/ml for CFA/I and CFA/II, respectively). As early as 1 week after a single oral immunization with the whole-cell component of the ETEC vaccine, large amounts of IFN--y were generated in the supernatants of PBMC exposed for 48 h to either of the CFAs (Fig.  3) . In 7 of 10 vaccinees, in vitro stimulation of PBMC by either of the CFAs resulted in considerable production of IFN--y, particularly in response to CFA/II (arithmetic means of IFN-'y, 144 and 439 mU/ml for CFA/I and CFA/II, respectively). A vaccinee was considered to be a responder when the amounts of IFN-,y in supernatants exceeded the arithmetic mean in nonimmunized controls by at least 2 standard deviations, i.e., more than 120 and 70 mU of IFN-,y per ml in response to in vitro stimulation by CFA/I and CFA/II, respectively. Accordingly, 7 of 10 vaccinees responded with substantial IFN--y production after only a single oral dose of the ETEC vaccine (Fig. 3) .
These results were confirmed by the determination of the number of IFN-y-secreting cells in the peripheral blood of four volunteers before and 8 days after one oral dose of the ETEC vaccine. Prior to vaccination, none of the four volunteers had more than eight IFN-y-secreting cells per 106 PBMC cocultured with either CFA/I or CFA/II. After immunization, the numbers of IFN-y-secreting cells in PBMC cultures exposed to CFA/I and CFA/II were increased in three of four volunteers examined (Table 1) . We did not find any relation between the magnitude of proliferative responses and either levels of For control purposes, we also evaluated whether lipopolysaccharide (LPS) derived from the vaccine strains (i.e., purified 078 and 06 LPS [1] ) could induce IFN--y production as well as cell proliferation of PBMC isolated from nonimmunized volunteers. We were unable to evoke either type of response with LPS (data not shown). It can therefore be excluded that endotoxin contamination of the CFAs accounted for the T-cell responses recorded in this study.
DISCUSSION
In previous studies, we have demonstrated the appearance of vaccine-specific B cells in the blood of human volunteers orally immunized with a prototype ETEC vaccine (34) . We have now examined whether oral administration of this vaccine would induce the appearance of antigen-specific T cells in peripheral blood. The two parameters most frequently used for identifying antigen-specific T cells are proliferation and production of cytokines upon in vitro culture in the presence of specific antigen. However, even though they are specifically induced, the different cytokines are not antigen specific, since their role in immune responses is often to augment and/or limit the number of effector cells in a nonspecific way.
In the present study, we have shown that oral immunization of human volunteers with the whole-cell component of a prototype ETEC vaccine induced the appearance of PBMC with the ability of proliferating in vitro when stimulated by either of two of the major protective antigens of the vaccine, i.e., CFA/I and CFA/NI. Cell sorting experiments indicated that CFA-specific proliferative responses were accounted for mainly by CD4+ T cells and, to a lesser degree, by CD8+ T cells. Since IgA antibody responses are highly T cell dependent (23) , it is likely that the CD4+ T cells which proliferated upon coculture with the CFAs comprised CFA-specific T-helper cells, capable of providing help to cognate B cells. We cannot rule out the possibility that the CD8+ T cells identified in this study also comprised T-helper cells, especially in view of recent reports indicating that some CD8+ T-cell clones can support the proliferation of human B cells (24) and even their differentiation into antibody-secreting cells (24, 25) . Nor can we rule out the possibility that the CD4+ T cells, and the CD8+ T cells for that matter, which proliferated in response to in vitroadded CFAs also comprised suppressor and/or cytotoxic cells, as has been reported by others (15, 25, 31) .
The modest T-cell proliferative responses recorded probably reflect the fact that intestinal administration of the ETEC vaccine induced only relatively small numbers of antigenspecific T-cell precursors in the circulation. Consistent with this interpretation are the facts that (i) levels of bioassayable IL-2, a major T-cell growth factor (5) (28) , and regulates electrolyte secretion (12) and the permeability of the intestinal epithelium (20) . Our findings suggest that determining IFN-,y responses in peripheral blood may be more adequate than measuring the proliferation of PBMC to vaccine components for monitoring vaccine-induced T-cell activation. We found that the preimmune levels of IFN-,y in PBMC cultures exposed to the CFAs were negligible before immunization and increased dramatically in the majority (70%) of the vaccinees after only a single oral dose of vaccine. This was confirmed by the determination of numbers of IFN-,y-secreting cells among PBMC exposed in vitro to CFAs prior to and following oral ETEC immunizations. For this reason, we propose that determination of IFN-,y levels to in vitro added vaccine antigens represents a good proxy measurement of vaccine-induced T-cell responses.
To conclude, we have demonstrated the appearance of vaccine-specific T cells in peripheral blood of orally immunized volunteers with the capacity to proliferate and to produce IFN--y upon in vitro stimulation with vaccine antigens. We have previously shown that the prototype ETEC vaccine, when delivered orally, elicits a significant intestinal antibody response and a poor serum response (1) . In other words, this vaccine appears chiefly to stimulate local mucosal immunity in the gut. We therefore propose that the responses of PBMC documented in this study were the reflection of intestinal T-cell activation. By analogy with intestinal B cells, these intestinal T cells were probably induced by oral immunization to enter the peripheral blood compartment, presumably before homing back to the intestine and other mucosal surfaces.
